Order Article Reprints

Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, Innominato PF, Bouchahda M, Adam R, Lévi F. Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers. 2022; 14(4):896. https://doi.org/10.3390/cancers14040896

Karaboué, Abdoulaye, Thierry Collon, Ida Pavese, Viviane Bodiguel, Joel Cucherousset, Elda Zakine, Pasquale F. Innominato, Mohamed Bouchahda, René Adam, and Francis Lévi. 2022. "Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer" Cancers 14, no. 4: 896. https://doi.org/10.3390/cancers14040896

Karaboué, A., Collon, T., Pavese, I., Bodiguel, V., Cucherousset, J., Zakine, E., Innominato, P. F., Bouchahda, M., Adam, R., & Lévi, F. (2022). Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers, 14(4), 896. https://doi.org/10.3390/cancers14040896